National Institutes of Health: Myelodysplastic Syndromes trials

The registry lists 136 Myelodysplastic Syndromes studies with National Institutes of Health as lead sponsor. 19 are open to participants now and 43 have results posted.

Early Phase 1 1Phase 1 66Phase 2 64Phase 3 6No phase 14(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
• CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
• T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
• A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)CompletedNCT00072969Phase 2
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
• Experimental Bone Marrow Transplant ProtocolCompletedNCT00061581Phase 2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
• A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)CompletedNCT00045396Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00027872Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Blood and Marrow Transplant Clinical Research NetworkCompletedNCT00023530Not applicable
• Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00019656Phase 1
• Thalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT00015990Phase 2
• Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic MalignanciesCompletedNCT00013533Early Phase 1
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
• Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedNCT00005942Phase 1/2
• Tipifarnib in Treating Patients With Myelodysplastic SyndromesCompletedNCT00005845Phase 1
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
• Leucovorin for the Treatment of 5 q Minus SyndromeCompletedNCT00004997Phase 2
• Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00004918Phase 1/2
• 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00003997Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002798Phase 3
• The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood CancersCompletedNCT00001873Phase 2
• A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic SyndromeCompletedNCT00001839Phase 2
• HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological MalignanciesCompletedNCT00001748Phase 1
• Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older AdultsCompletedNCT00001637Phase 2
• Bone Marrow Transplant Studies for Safe and Effective Treatment of LeukemiaCompletedNCT00001623Not applicable
• Cord Blood Stem Cell Transplantation Study (COBLT)CompletedNCT00000603Phase 2
• T-Cell Depletion in Unrelated Donor Marrow TransplantationCompletedNCT00000591Phase 3